NAS:MDCO (USA) Also trade in: Germany

The Medicines Co

$ 34.23 1.24 (3.76%)
Volume: 3,616,316 Avg Vol (1m): 924,839
Market Cap $: 2.53 Bil Enterprise Value $: 3.14 Bil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -26.64
Net Current Asset Value -8.77
Tangible Book -3.71
Projected FCF -25.75
Median P/S Value -0.06
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.25
Cash-To-Debt ranked lower than
79.98% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
MDCO: 0.25
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.2, Med: 10000, Max: 10000
Current: 0.25
0.2
10000
Debt-to-Equity -10.73
Debt-to-Equity ranked lower than
100.00% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
MDCO: -10.73
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -35.61, Med: 0.41, Max: 31.22
Current: -10.73
-35.61
31.22
Debt-to-EBITDA -4.35
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
MDCO: -4.35
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -6.13, Med: 2.23, Max: 7.05
Current: -4.35
-6.13
7.05
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.28
DISTRESS
GREY
SAFE
Beneish M-Score -4.59
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -28.2%
WACC 15.35%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -2705.25
Operating Margin ranked lower than
95.38% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
MDCO: -2705.25
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -3035.81, Med: -5.27, Max: 14.87
Current: -2705.25
-3035.81
14.87
Net Margin % -3456.66
Net Margin ranked lower than
95.76% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
MDCO: -3456.66
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3456.66, Med: -11.87, Max: 26.38
Current: -3456.66
-3456.66
26.38
ROA % -26.08
ROA ranked lower than
80.14% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
MDCO: -26.08
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -54.95, Med: -4.3, Max: 24.65
Current: -26.08
-54.95
24.65
ROC (Joel Greenblatt) % -1582.08
ROC (Joel Greenblatt) ranked lower than
81.40% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
MDCO: -1582.08
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1582.08, Med: 37.86, Max: 402.9
Current: -1582.08
-1582.08
402.9
3-Year Total Revenue Growth Rate -72.50
3-Year Revenue Growth Rate ranked lower than
97.24% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
MDCO: -73.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate -36.10
3-Year EBITDA Growth Rate ranked lower than
100.00% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
MDCO: -31.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -16.60
3-Year EPS w/o NRI Growth Rate ranked lower than
98.64% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
MDCO: -16.6
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» MDCO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MDCO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare SHSE:600380 SZSE:300558 TSE:4540 TSE:4555 HKSE:01558 SHSE:600079 SZSE:002038 SHSE:603707 HKSE:00867 HKSE:00460 SHSE:600521 BOM:532296 XLJU:KRKG SHSE:600062 SHSE:600511 HKSE:02005 SZSE:300630 NAS:SUPN NAS:IRWD TSX:APHA
Traded in other countries MZN.Germany
Address 8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.

Ratios

Current vs industry vs history
EV-to-EBIT -16.61
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
MDCO: -16.61
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -157.1, Med: 8.7, Max: 211.9
Current: -16.61
-157.1
211.9
EV-to-EBITDA -16.87
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
MDCO: -16.87
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -221.1, Med: 10.5, Max: 221.5
Current: -16.87
-221.1
221.5
EV-to-Revenue 510.94
EV-to-Revenue ranked lower than
96.86% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
MDCO: 510.94
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 2.8, Max: 485.4
Current: 510.94
0.4
485.4
Current Ratio 4.09
Current Ratio ranked higher than
53.68% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
MDCO: 4.09
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.75, Med: 3.97, Max: 10.09
Current: 4.09
0.75
10.09
Quick Ratio 4.07
Quick Ratio ranked higher than
61.52% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
MDCO: 4.07
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.71, Med: 3.47, Max: 9.44
Current: 4.07
0.71
9.44
Days Inventory 113.44
Days Inventory ranked lower than
96.42% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
MDCO: 113.44
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 72.24, Med: 130.78, Max: 280.04
Current: 113.44
72.24
280.04
Days Payable 592.96
Days Payable ranked higher than
57.12% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
MDCO: 592.96
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 15.33, Med: 40.16, Max: 592.96
Current: 592.96
15.33
592.96

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.90
3-Year Share Buyback Rate ranked higher than
57.27% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
MDCO: -1.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -85.1, Med: -3.55, Max: 0
Current: -1.9
-85.1
0

Valuation & Return

Current vs industry vs history
Earnings Yield (Joel Greenblatt) % -6.02
Earnings Yield (Greenblatt) ranked lower than
81.89% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
MDCO: -6.02
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -28, Med: 0.6, Max: 15.2
Current: -6.02
-28
15.2
Forward Rate of Return (Yacktman) % -10.65
Forward Rate of Return ranked lower than
87.41% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
MDCO: -10.65
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -16.6, Med: 2.6, Max: 5.2
Current: -10.65
-16.6
5.2

More Statistics

Revenue (TTM) (Mil) $ 6.14
EPS (TTM) $ -2.87
Beta 2.63
Volatility % 51.42
52-Week Range $ 16.69 - 41.57
Shares Outstanding (Mil) 73.9

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N